By Kyle Jahner ( May 1, 2018, 10:27 PM EDT) -- A Federal Circuit panel Tuesday homed in on whether Teva Pharmaceutical s USA Inc.'s invention of three 40-milligram injections per week for its multiple sclerosis drug Copaxone was obvious in light of prior studies considering doses every other day, as a district court and the Patent Trial and Appeal Board have ruled....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.